Lilly: Emerging learnings in Spondyloarthritis (SpA): From clinical trials to clinical practice


Wollheim
English
Satellite Symposium
04 June 2020 17:30 - 19:00

Eli Lilly & Company welcomes you to the 2020 virtual EULAR Ixekizumab symposium entitled “Emerging learnings in Spondyloarthritis: From clinical trials to clinical practice”. These presentations are in line with the EMA-approved label of Ixekizumab as of May 27th 2020. For the latest approved Ixekizumab label please check the Lilly company profile on this platform and the EMA website. 

Agenda topics:

What are the ongoing unmet needs in SpA? 

  •  How are current recommendations reflecting medical advancements in SpA and informing treatment goals for these patients

How can clinical trials inform clinical practice? 

  • Clinical case discussions informed by recent data from Ixekizumab clinical trials and updated recommendations/ guidelines

Presentations

Title Time Add to calendar
Welcome and introduction
04 June 2020 17:30 - 17:35 Add to calendar
What are the ongoing unmet needs in SpA?
04 June 2020 17:35 - 17:55 Add to calendar
How can clinical trials inform clinical practice? Case 1
04 June 2020 17:55 - 18:15 Add to calendar
How can clinical trials inform clinical practice? Case 2
04 June 2020 18:15 - 18:35 Add to calendar
Panel discussion and Q&A
04 June 2020 18:35 - 18:55 Add to calendar
Conclusion and Symposium close
04 June 2020 18:55 - 19:00 Add to calendar